MYC and angiosarcoma: The significant upregulation of the miR-17-92 cluster in MYC-amplified angiosarcomas could potentially serve as a biomarker to identify patients with a more aggressive form of the disease, aiding in the stratification of patients and the tailoring of therapeutic strategies [101].